Impact of Adjuvant Therapy on Breast Cancer Cure Rates
Author Information
Author(s): J.W. Gamell, R.L. Vogel, I.W. McLean
Primary Institution: Veterans Administration Medical Center and University of Louisville School of Medicine
Hypothesis
How does adjuvant therapy affect the cure rate and survival time in stage 2 breast carcinoma patients?
Conclusion
The study suggests that the log-rank test is more sensitive to increases in survival time than to increases in the cured fraction in clinical trials of adjuvant therapy for stage 2 breast cancer.
Supporting Evidence
- A 50% enhancement of median survival time led to a survival increase detectable in 780 of 1000 trials.
- A 50% enhancement of cured fraction led to a detectable increase in only 449 of 1000 trials.
- The log-rank test may not effectively distinguish between increased survival time and increased cure rates.
Takeaway
This study looked at how treatment helps breast cancer patients live longer and whether it actually cures them. It found that just living longer doesn't always mean more people are cured.
Methodology
An algorithm was constructed to simulate clinical trials with varying cured fractions and median survival times, analyzing the results using the log-rank test.
Limitations
The findings depend on the model used, which may not accurately reflect the true parameters of patients with stage 2 breast carcinoma.
Participant Demographics
Patients were randomly assigned ages following a Gaussian distribution with a mean of 55.2 years and a standard deviation of 12.9 years.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website